- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02024100
Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS)
Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure in Hypertensive Patients With Metabolic Syndrome
The study is to identify the effectiveness of Eprosartan on pulse pressure in hypertensive patients with metabolic syndrome
-Definition of pulse pressure (PP): Difference between systolic and diastolic blood pressure produced one heart beat.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Primary Objective
-To assess the changes of pulse pressure at 12 weeks
Secondary Objectives
- To assess the changes of pulse pressure at 4, 24 weeks
- To assess the changes of systolic blood pressure and diastolic blood pressure at each visit
- Percentage of responder rate* at each visit and time to get normalized BP from enrollment
- Responder rate at last visit
- To assess IIEF-5 (5-item Version of the International Index of Erectile Function) score at enrollment and 24 weeks (percentage of patients with ED according to IIEF-5, Changes of IIEF-5 domains)
- Percentage of patients with erectile dysfunction (ED) according to IIEF-5 and changes of PP in subgroup (age 65, body mass index (BMI) 23, diabetes mellitus, dyslipidemia, benign prostate hypertrophy)
- Analysis of correlation between ED and concomitant disease and concomitant medications in patients who received Eprosartan
- Score changes of Framingham 10-year Coronary Heart Disease (CHD) risk at 1st visit, 4th visit
- Percentages of Eprosartan monotherapy and multiple antihypertensive therapies at enrollment and last visit
- Reason for treatment discontinuation (Inadequate BP control, adverse events, others)
Adverse events
- Responder rate: SBP <140mmHg and DBP <90mmHg (SBP <140mmHg and DBP <85mmHg for patients with diabetes mellitus)
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
Bundang-gu
-
Seongnam-si, Bundang-gu, Korea, republiek van, 463-717
- Werving
- Seoul National University Bundang Hospital
-
Contact:
- Chang Hwan Yoon, MD
-
Hoofdonderzoeker:
- Chang Hwan Yoon, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- 20-80 years old patient at the 1st visit
- Patient who is determined to prescribe Eprosartan for hypertension (patient with at least one of the following conditions) (1) Newly diagnosed hypertension (2) Inability to tolerate hypertension (for example: adverse event) (3) Lack of response to current antihypertensive medications
Metabolic syndrome patient (fulfill 3 or more components before enrollment) (1) Waist circumference (>90 for men, >80 for women) (2) Triglycerides (≥150mg/dl) (3) HDL cholesterol (<40mg/dl for men, <50mg/dl for women) (4) SBP≥130mmHg or DBP≥85mmHg or on antihypertensive medications) (5) Fasting glucose level (≥100mg/dl) or on antidiabetic medications
- MS diagnosis origin: Korean diabetes association
Exclusion Criteria:
- Patients who is administered with 3 or more than 3 antihypertensive drugs
- Patients who is contraindicated with Eprosartan by the product label
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
To assess the changes of pulse pressure at 12 weeks
Tijdsspanne: 12 weeks
|
Calculating pulse pressure at 3rd(12weeks) visit and it will be presented in descriptive statistics quantity
|
12 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
- changes of pulse pressure at 4, 24 weeks - changes of blood pressure at 4, 12, 24 weeks - Duration to get normalized BP - assess IIEF-5 score - Score changes of Framingham 10-year CHD risk
Tijdsspanne: 24 weeks
|
|
24 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Chang Hwan Yoon, MD, Seoul National University Bundang Hospital
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HD_EPR_OS2013
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .